FilingSEC EDGAR6-K
Radiopharm Theranostics Reports Increased Net Loss for Fiscal Year 2026
· SEC accepted
StageEarnings Release
Filing content
Radiopharm Theranostics reported a 50.3% increase in net loss for fiscal year 2026, driven by higher research and development expenditures for ongoing clinical studies.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…